DHR
Danaher Corporation
Healthcare · Diagnostics & Research · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The dividend sub-score of 20.0 out of 20 anchors the total model score at 58.2 by contributing the single largest component, reflecting exceptional FCF payout ratio discipline and dividend per share consistency as derived from the FY2025 10-K.
- The financial health sub-score of 16.0 contributes meaningfully to the score, as the filing data indicates a leverage ratio and interest coverage level that the model classifies as sound for a company of this balance sheet scale.
- The profitability sub-score of 13.2 provides a moderate positive contribution, reflecting acceptable net margins and operating margins reported in the filing, though not at a level that would push the overall score materially higher.
Why Not Higher
- The growth sub-score of 7.5 out of 20 significantly constrains the total model score, as weak year-over-year revenue and earnings growth metrics from the FY2025 10-K filing directly reduce the model's assessment of DHR's current fundamental trajectory.
- A theme score of 0.0 out of 20 means DHR captured no credit from macro thematic exposure in the model, representing a structural ceiling that prevents the score from reaching higher ranges even if other financial metrics were to improve.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Danaher Corporation is a U.S.-based science and technology conglomerate operating primarily within the healthcare diagnostics and research sector. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services across life sciences tools, diagnostics platforms, and environmental and applied solutions. Its portfolio includes well-known brands serving biopharma, clinical laboratory, and water quality end markets, and the company has historically grown through a disciplined acquisition strategy known as the Danaher Business System. The model assigned DHR an overall score of 58.2/100, which reflects a genuinely mixed profile: the dividend sub-score is the standout at 20.0 out of 20, indicating strong free cash flow payout discipline, a consistent dividend per share streak, and solid FCF coverage of dividends. Financial health also scores well at 16.0, pointing to a manageable leverage position and healthy interest coverage as reported in the FY2025 10-K filing. However, the growth sub-score of 7.5 and momentum sub-score of 8.4 reflect meaningful softness in recent revenue and earnings trajectory, which is consistent with the post-pandemic normalization that has weighed on diagnostics and life sciences instrument demand. Profitability at 13.2 is moderate but not top-tier, and the theme score of 0.0 indicates the model did not map DHR to any of the macro thematic categories it tracks, limiting upside in that dimension. The key research tradeoff here is between a financially sound, dividend-disciplined business with a long operating history and the current cyclical revenue headwinds that have suppressed near-term growth and operational momentum metrics.
Plain English
Danaher is a large U.S. healthcare and science tools company — it makes the equipment and testing systems that hospitals, drug companies, and research labs rely on every day. The model score of 58.2 out of 100 with a Medium risk rating tells a researcher that this is a financially stable, dividend-consistent company, but one that is currently experiencing a slowdown in revenue and earnings growth that limits its overall score. It scores best as a dividend income research candidate, not an aggressive growth one, meaning it may appeal more to researchers focused on cash flow sustainability than rapid expansion.
Bull Case vs. Bear Case
Bull Case
- The dividend sub-score of 20.0 out of 20 — the maximum possible — signals that DHR's free cash flow coverage of its dividend, dividend per share streak, and dividend growth CAGR are all exemplary by the model's standards, making it a high-conviction candidate within dividend income research profiles.
- The financial health sub-score of 16.0 out of 20 reflects a well-structured balance sheet with manageable leverage and strong interest coverage as reported in the FY2025 10-K, suggesting the company has the financial resilience to sustain dividends and fund operations through cyclical downturns.
- Danaher's diversified exposure across life sciences tools, diagnostics, and environmental solutions provides some revenue diversification, meaning a downturn in one segment does not necessarily compress the entire business, which supports the medium risk designation.
Bear Case
- The growth sub-score of 7.5 out of 20 is the model's clearest signal that year-over-year revenue, net income, and EPS growth have been materially weak in the FY2025 filing period, reflecting the ongoing normalization of demand in diagnostics and life sciences instruments following the pandemic-era surge.
- The momentum sub-score of 8.4 out of 20 indicates that quarterly improvements in revenue, earnings, and margins have been limited, suggesting the recovery in business fundamentals has not yet gained meaningful traction in recent quarters.
- The theme score of 0.0 out of 20 means DHR did not register exposure to any of the macro thematic categories tracked by the model, which structurally caps its total score and reduces its attractiveness for researchers seeking companies aligned with high-growth macro trends.
What Could Change the Picture
Bullish Triggers
- A meaningful improvement in the growth sub-score — driven by demonstrable year-over-year revenue and net income recovery in a subsequent 10-K or quarterly filing — would signal that life sciences and diagnostics end-market normalization has reversed, which could lift the overall model score toward the 65 to 70 range.
- Evidence of positive quarterly momentum across revenue, earnings, and margins in consecutive periods would raise the momentum sub-score from 8.4, indicating that operational improvement is compounding rather than stalling, which would strengthen the research case under the dividend income profile.
Bearish Triggers
- Deterioration in the financial health sub-score — for example, a materially higher leverage ratio or declining interest coverage reported in a future 10-K — would undermine the current balance sheet strength that partially justifies the 58.2 score and the medium risk designation.
- Any evidence in future filings of a reduction in free cash flow generation that threatens the FCF coverage of the dividend would directly challenge the 20.0 dividend sub-score and could cause the model score and research label to decline significantly.
Red Flags
- The combination of a low growth sub-score (7.5) and low momentum sub-score (8.4) in the same filing period raises a research concern that revenue and earnings weakness may be more than transitory, warranting close attention to segment-level demand recovery in future filings.
Risk Profile
Medium RiskThe Medium risk rating for DHR reflects a company with a structurally sound balance sheet and strong dividend coverage, offset by meaningful near-term cyclical pressure on growth and operational momentum that introduces uncertainty about the pace and timing of a fundamental recovery.
Key Catalysts to Watch
The primary catalyst to watch is the pace of end-market recovery in life sciences tools and diagnostics demand, which would be evidenced by improving year-over-year revenue and earnings growth in subsequent SEC filings; sustained free cash flow generation relative to dividend payments is also a key metric to monitor for the dividend income research profile.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.